Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $24.67 Average PT from Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has been assigned a consensus recommendation of “Buy” from the nine analysts that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $22.56.

A number of equities research analysts have issued reports on CAPR shares. HC Wainwright restated a “buy” rating and set a $24.00 price target (down from $77.00) on shares of Capricor Therapeutics in a report on Friday, July 11th. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Piper Sandler restated an “overweight” rating and set a $20.00 price target on shares of Capricor Therapeutics in a report on Friday, July 11th. Jones Trading decreased their price target on shares of Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday, June 25th. Finally, Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Monday.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 700,243 shares during the period. Farallon Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $31,056,000. Geode Capital Management LLC lifted its stake in shares of Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock valued at $12,139,000 after buying an additional 241,279 shares during the period. Woodline Partners LP lifted its stake in shares of Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after buying an additional 99,384 shares during the period. Finally, Altium Capital Management LLC lifted its stake in shares of Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after buying an additional 429,000 shares during the period. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 0.8%

Shares of NASDAQ:CAPR opened at $7.24 on Monday. The stock has a market capitalization of $330.72 million, a PE ratio of -5.10 and a beta of 0.82. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The firm has a fifty day moving average price of $10.28 and a 200 day moving average price of $11.98.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). The business had revenue of $2.73 million during the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter in the prior year, the company posted ($0.31) earnings per share. On average, sell-side analysts forecast that Capricor Therapeutics will post -1.21 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.